August 9, 2024 06:02 PM EDTUpdated August 12, 08:46 AM
Pharma
FDA+

Lykos’ MD­MA-as­sist­ed PTSD treat­ment re­ject­ed by FDA af­ter trou­bled tri­al and push­back from ex­perts

Max Bayer

Pharma Reporter

The FDA has re­ject­ed Lykos’ MD­MA-as­sist­ed treat­ment for pa­tients with post-trau­mat­ic stress dis­or­der, a ma­jor set­back for the com­pa­ny that had hoped to trans­late more …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Stem cell start­up spun out of George Church’s lab rais­es $75M

Here's what to­day's Fed rate cut means for biotech, phar­ma and ven­ture cap­i­tal

Edge­wise’s stock surges as heart drug pass­es ear­ly safe­ty test

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

FDA re­jects Van­da’s treat­ment for di­ges­tion con­di­tion, com­pa­ny re­bukes agen­cy's ac­tions

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times